Nanoparticle Carriers for Targeted Pulmonary Drug Delivery

Prepared by

Shahd Fuad Al-Tarawneh

Supervised by

Dr. Eman AL-Zmaily

A Thesis

Submitted to Faculty of Pharmacy as a Partial Fulfillment of the Requirement for Master Degree in Pharmaceutical Sciences

December 2019
نموذج التفويض

أنا شهد فؤاد الطراونة، أفوض جامعة الاسراء بتزويد نسخ من رسالتي للمكتبات أو المؤسسات أو الهيئات أو الأشخاص عند طلبهم حسب التعليمات النافذة في الجامعة.

التاريخ: 13-12-2019

Authorization Form

I Shahd Fuad Al-Tarawneh, authorizes Al Isra University to supply copies of my Thesis to libraries or establishments or individuals on request, according to AL Isra University regulations.

Date: 13-12-2019
COMMITTEE DECISION

This Thesis (Nanoparticle Carriers for Targeted Pulmonary Drug Delivery) was Successfully Defended and Approved on ---------------

<table>
<thead>
<tr>
<th>Examination Committee</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Eman Darweesh Misbah Al- Zmaily (Chariman)</td>
<td></td>
</tr>
<tr>
<td>Assistant Professor – Isra University</td>
<td></td>
</tr>
<tr>
<td>Dr. Jamal Al-Youssef Al-Krad (Internal Examiner)</td>
<td></td>
</tr>
<tr>
<td>Associate Professor – Isra University</td>
<td></td>
</tr>
<tr>
<td>Dr. Shereen Mashhoor Assaf (External Examiner)</td>
<td></td>
</tr>
<tr>
<td>Associate Professor – Jordan University of Science &amp; Technology</td>
<td></td>
</tr>
</tbody>
</table>
Nanoparticle Carriers for Targeted Pulmonary Drug Delivery

By

Shahd Fuad Al-Tarawneh

December, 2019

ABSTRACT

The pulmonary route for drug delivery offers multiple advantages over other routes of drug administration owing to its large surface area, high vascularization and thin blood-alveolar barrier. Drug delivery by this route is convenient to patients, less painful (non-invasive) and can be employed for local and systemic delivery of active pharmaceutical ingredients (APIs). The use of dry powder inhalers (DPI) enables the delivery of APIs to the lung with favorable properties. To do that, powder should possess critical quality attributes pertinent to size, flowability and ability to reach the lower parts of the respiratory system. Nano aggregate formulations are suitable technology that enables the development of successful DPIs. Therefore, the aim of this project is to employ Nano technology to develop iron oxide containing nanoparticles using model API- dactinomycin. Iron oxide nanoparticles will serve as a carrier for directing the API to the targeted site of action within the lung. The development and optimization of iron oxide nanoparticles was carried out employing Quality by Design (QbD) methodology. Nanoparticles were built up from iron oxide that was chemically prepared using bottom up method. Two polymers were investigated (chitosan and sodium alginate). The quantitative method for the analysis of dactinomycin by HPLC was validated according ICH guidelines. That was followed by screening studies for iron oxide nanoparticles development. The produced dactinomycin containing nanoparticles was characterized for mass median aerodynamic diameter (MMAD), fine particle fraction (FPF), burst effect, iron
oxide FPF and the emitted dose in the initial screening studies to investigate the most suitable input and process parameters to take to an optimization study by employing QbD principles through Design of Experiment. Results revealed the superiority of the nanoparticle aggregates containing DPIs in delivering high emitted dose, high FPF and targeted MMAD. Design space in QbD analysis showed that when using a concentration of API between 4% to 5% w/w accompanying with polymer concentration ranging from 0.5% to 0.8% w/w using sodium alginate or concentration of API is between 2.7% to 4% w/w accompanying with polymer concentration ranging from 1.2% to 2% using sodium alginate will get the desired outcome. Similarly, favorable critical quality attributes (CQA) results were attained with chitosan as a polymer, when API concentration was between 4.5% to 5% w/w and polymer concentration ranging from 0.5% to 0.8% w/w. Therefore, the outcome of this research project could be a starting point for further work to optimize and assess DPI for delivering other drugs employing iron oxide-polymer nano aggregates.
Dedication

I dedicate this thesis to my lovely mother. Because she is the one who made me the person I am, she is and will be always my role model.

I also dedicate this thesis to my super hero my father, this accomplishment would not have been possible without his encouragement.

To all my family members, my brother and my sisters who have been a constant source of support and encouragement also to the soul that has always been by my side thank you.

Shahd Fuad.
Table of Contents

ABSTRACT ........................................................................................................................................ iv
Dedication .......................................................................................................................................... vi
Table of Contents .............................................................................................................................. vii
List of Figures ..................................................................................................................................... vii
List of Tables ...................................................................................................................................... x
Acknowledgement ........................................................................................................................... xiv
List of Abbreviations .......................................................................................................................... xv

Chapter One Introduction .................................................................................................................. 1

1.1 Background .................................................................................................................................. 2
  1.1.1 Cancer statistics ....................................................................................................................... 4
  1.1.2 Metal nanoparticles .................................................................................................................. 5
    1.2.2.1 Iron oxide .......................................................................................................................... 6
  1.1.3 Dactinomycin ........................................................................................................................... 7
  1.1.4 Natural biodegradable polymer ................................................................................................ 9
    1.1.4.1 Chitosan ............................................................................................................................. 10
    1.1.4.2 Alginates ............................................................................................................................ 10
  1.1.5 Mechanisms of drug deposition within the lung ........................................................................ 11
  1.1.6 Dry powder inhalers ............................................................................................................... 12
  1.1.7 Quality by Design (QbD) ....................................................................................................... 14

1.2 Study aim and objectives .............................................................................................................. 15

Chapter Two Literature Review ........................................................................................................ 17

2.1 Targeted drug delivery ................................................................................................................. 18

2.2 Nanoparticles .............................................................................................................................. 19
  2.2.1 Iron oxide nanoparticles ......................................................................................................... 20
  2.2.2 Toxicity of metal oxide nanoparticles (MONP) ................................................................... 21
    2.2.2.1 Toxicity of iron oxide nanoparticles ................................................................................. 21
  2.3 Dry powder inhalers (DPI) ......................................................................................................... 22
    2.3.1 Limitations of capsule-based dry powder inhalers ............................................................... 25
3.2 Methods ......................................................................................................................... 28
  3.2.1 Dactinomycin analytical method validation ................................................................. 28
    3.2.1.1 HPLC .................................................................................................................. 28
    3.2.1.2 Specificity of dactinomycin .................................................................................... 29
    3.2.1.3 Specificity of iron oxide and polymers (chitosan, Na-Alginate) ......................... 29
    3.2.1.4 Linearity ................................................................................................................ 30
    3.2.1.5 Accuracy .............................................................................................................. 30
    3.2.1.6 Precision .............................................................................................................. 30
    3.2.1.7 Limit of detection (LOD) and limit of quantification (LOQ) ......................... 31
  3.2.2 Fourier transform infrared (FTIR) spectroscopy analysis ............................................ 31
  3.2.3 Iron oxide nanoparticles preparation .......................................................................... 31
  3.2.4 Coating nanoparticles with the polymer: ................................................................. 32
  3.2.5 Development of dactinomycin, iron oxide nanoparticles and polymer combination ......................................................................................................................... 33
  3.2.6 Aerodynamic particle size analysis using Next Generation Impactor (NGI) ........... 34
  3.2.7 Content uniformity .................................................................................................... 35
  3.2.8 Mass median aerodynamic diameter (MMAD calculation) ..................................... 35
  3.2.9 In-vitro drug release studies ...................................................................................... 36
  3.2.10 Quality by Design (QbD) analysis ............................................................................ 36

Chapter Four ............................................................................................................................. 40

Dactinomycin Analytical Process Validation ........................................................................ 40

4.1 HPLC method for quantification of Dactinomycin .......................................................... 41
  4.1.1 Specificity of iron oxide and polymers (chitosan, Na-Alginate) .............................. 42
  4.1.2 Linearity ................................................................................................................... 43
  4.1.3 LOD and LOQ ........................................................................................................... 44
  4.1.4 Accuracy .................................................................................................................... 44
  4.1.5 Precision .................................................................................................................... 45

4.2 FTIR analysis .................................................................................................................. 46

Chapter Five ........................................................................................................................... 47

Quality by Design (QbD) for Optimizing Dactinomycin Containing Nanoparticles ........... 47

5.1 Results and Discussion .................................................................................................. 48
  5.1.1 Initial screening studies ............................................................................................. 48
  5.1.2 Elements of DoE ........................................................................................................ 50
5.1.3 DoE .......................................................................................................................... 50
5.1.4 Model verification ...................................................................................................... 52
5.1.5 Analysis of variance (ANOVA) results ...................................................................... 60
5.1.6 Regression model equations for CQAs ..................................................................... 62
5.1.7 Effect of critical input parameters (Factors) on CQA/Responses ......................... 63
5.1.8 Prediction of design space ....................................................................................... 71

Chapter Six ....................................................................................................................... 74

Conclusion and Future Recommendations .......................................................................... 74
  6.1 Conclusion .................................................................................................................. 75
  6.2 Future recommendation ............................................................................................... 76

References ......................................................................................................................... 77

Appendix 1 .......................................................................................................................... 82
List of Figures

Chapter one:

Figure 1. 1 Dactinomycin structure, adopted from (USP monographs, 2011) ........................................ 8

Figure 1. 2 Schematic diagram highlighting particle deposition process in the respiratory tract. 
Adopted from (medescape, 2019) ........................................................................................................ 12

Figure 1. 3 Schematic diagram of dry powder inhaler formulations and dispensing powder 
mechanisms. (A) Drug-only formulation (drug agglomerates); (B) Carrier-based formulation. 
...................................................................................................................................................... 14

Chapter Two:

Figure 2. 1 Basic Steps Involved in using Nanoparticles for Targeted Drug Delivery adopted from 
(Singh et al., 2017) ............................................................................................................................ 19

Figure 2. 3 Marketed DPI products: (A) Aerolizer® (Novartis); (B) Handihaler® (Boehringer 
Ingelheim); (C) Accuhaler® (GlaxoSmithKline); (D) Turbuhaler® (AstraZeneca) ..................... 24

Chapter Three:

Figure 3. 1. Dactinomycin containing nanoparticles formation process ............................................ 34

Chapter Four:

Figure 4. 1 Overlaid chromatograms from bottom to top 1: reference standard, 2: blank sample, 3: 
sample 1 and 4: sample 2 .................................................................................................................................. 41

Figure 4. 2 HPLC Chromatogram of chitosan sample, no peak appeared at the retention time of 
23min. .................................................................................................................................................... 42

Figure 4. 3 HPLC Chromatogram of Na-Alginate sample no peak is appeared at retention time 
23min. .................................................................................................................................................... 43

Figure 4. 4 Beer-Lamberts calibration curve for Dactinomycin ranging from 62.5-1000 µg/ml 
(mean ± SD), n=3 measured at 254 nm .................................................................................................... 44

Figure 4. 5 FTIR Spectra for dactinomycin reference standard, crude dactinomycin sample, purified 
sample using media 1 and purified sample using media 2. Samples were scanned over a range 
from 450- 4000 cm-1 .................................................................................................................................. 46

Chapter Five:

Figure 5. 1 Deposition of the nanoaggregates onto the NGI apparatus highlighting the dark brown 
powder collected from tray 1-8 which represents the dactinomycin loaded -IONP. ............... 49
Figure 5. 2 Summary plot of the six responses (CQA) of fit showing model fit (R2), predictability (Q2), model validity and reproducibility. ................................................................. 52

Figure 5. 3 Variable importance plot (VIP) of six responses which showed whether each term was important. ................................................................. 53

Figure 5. 4 The distance to model plot of individual runs to identify the outlier runs (highlighted with arrows). ................................................................. 54

Figure 5. 5 Summary plot of the four responses CQA of fit showing model fit (R2), predictability (Q2), model validity and reproducibility after exclusion of outliers and removal of non-important terms. ................................................................. 55

Figure 5. 6 The normal probability plot of residuals clarify that all responses plots are random and normally distributed (within the range -4 to +4 SD). ................................................................. 56

Figure 5. 7 The residuals versus predicted response for all the responses confirm the validity of the models owing to its randomness................................................................. 57

Figure 5. 8 The residual versus run order plot shows a well randomness of run distribution which in turn indicates a good model. ................................................................. 57

Figure 5. 9 The residuals versus variables (polymer type) show randomness and having no pattern. 58

Figure 5. 10 The residuals versus variables (polymer concentration) show randomness and having no pattern ................................................................. 59

Figure 5. 11 The residuals versus variables (API concentration) show randomness and having no pattern ................................................................. 59

Figure 5. 12 The observed versus predicted plots of all responses that show linearity correlation of emitted dose, MMAD, burst effect, FFP, FPF-Theo and IFPF which corresponding with good model ................................................................. 60

Figure 5. 13 : Lack of fit plot showing standard deviation (SD) of the Lack of Fit, SD of pure error and SD of pure error multiplied by critical F-value. When the third bar is larger than the first, there is no lack of fit ................................................................. 61

Figure 5. 14 Regression coefficient plot of model terms for each CQA, showing the significance for each term (do not cross the zero line). ................................................................. 63

Figure 5. 15 Effect of API concentration and polymer concentration on IFPF ................................................................. 64

Figure 5. 16 Effect of API concentration and polymer concentration on MMAD ................................................................. 65

Figure 5. 17 Effect of API concentration and polymer concentration on FPF ................................................................. 66

Figure 5. 18 Effect of API concentration and polymer type on FPF ................................................................. 67
Figure 5. 19 Effect of API concentration and polymer type on burst effect ........................................... 68

Figure 5. 20 Effect of API concentration and polymer type on emitted dose ....................................... 69

Figure 5. 21 Effect of API concentration and polymer concentration on FPF-Theo............................. 70

Figure 5. 22 Effect of API concentration and polymer type on FPF-Theo ......................................... 71

Figure 5. 23 The sweet spot for optimal proportion ranking of factors (API concentration, polymer type (chitosan), polymer concentration) to obtaining the desired response values relating to FPF, MMAD, IFPF, FPF-Theo, burst effect and emitted dose. ................................................. 72

Figure 5. 24 The sweet spot for optimal proportion ranking of factors (API concentration, polymer type (sodium alginate), polymer concentration) to obtaining the desired response values relating to FPF, MMAD, IFPF, FPF-Theo, burst effect and emitted dose........................................ 73
List of Tables

Chapter Two:

Table 2.1 Types of Aerosol Delivery Devices (Pfizer, 2009) ................................................................. 22

Chapter Three:

Table 3.1 Polymers concentration for nanoparticles preparation ......................................................... 32
Table 3.2 List of factors with their details that were used in DoE .......................................................... 37
Table 3.3 List of CQA/responses with their details that were used in DoE study ..................................... 37
Table 3.4 Summary of concentrations of API and Polymer employed in the DoE study highlighting the lower (-1), medium (0) and the higher (1) concentrations ................................................................. 38
Table 3.5 Worksheet of experiments that were generated by MODDE Software ..................................... 38

Chapter Four:

Table 4.1 Area under the curve for three concentrations of dactinomycin repeated three times on three days to show the intraday and interday reproducibility of the analytical technique (mean ± SD, n=3) ........................................................................................................................................ 45
Table 4.2 Precision of the analytical technique for dactinomycin .......................................................... 45

Chapter Five:

Table 5.1 The D-optimal design worksheet with the proportions of factors, CQA results, the total number of runs as well as the run order ............................................................................................................. 51
Table 5.2 Summary of results obtained from ANOVA ............................................................................. 61
Acknowledgement

I would like to express my gratitude to my supervisor Dr. Eman Zmaily for the valuable comments and remarks. She consistently allowed this project to be my own work but steered me in the right direction whenever she thought I needed it.

I express my thanks and gratitude to Al Isra University, to all my doctors especially Dr. Suha Abudoleh, Dr. Samer Al-Ali and Dr. Amjad Abuirmeileh for encouragement, help and support.

I would also like to acknowledge Miss Rasha Abuthawabeh for her unlimited giving and all my friends and colleagues for their help, unfailing support, continuous encouragement and charity throughout my years of study.

Finally, I must express my thanks to the members of examination committee for their suggestion and for devoting their time to read and evaluate my work.
### List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>CPP</td>
<td>Critical process parameter</td>
</tr>
<tr>
<td>CQA</td>
<td>Critical quality attributes</td>
</tr>
<tr>
<td>DoE</td>
<td>Design of experiment</td>
</tr>
<tr>
<td>ED</td>
<td>Emmitted dose</td>
</tr>
<tr>
<td>FPF</td>
<td>Fine particle fraction</td>
</tr>
<tr>
<td>FDA</td>
<td>Food drug administration</td>
</tr>
<tr>
<td>FTIR</td>
<td>Fourier-transform infrared spectroscopy</td>
</tr>
<tr>
<td>FPF-Theo</td>
<td>Fine particle fraction theoretical</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference of Harmonization</td>
</tr>
<tr>
<td>IFPF</td>
<td>Iron oxide fine particle fraction</td>
</tr>
<tr>
<td>IONP</td>
<td>Iron oxide nanoparticles</td>
</tr>
<tr>
<td>NGI</td>
<td>Next generation impactor</td>
</tr>
<tr>
<td>PLS</td>
<td>Partial least squares method</td>
</tr>
<tr>
<td>PDD</td>
<td>Pulmonary drug delivery</td>
</tr>
<tr>
<td>pMDIs</td>
<td>Pressurized metered dose inhalers</td>
</tr>
<tr>
<td>QbD</td>
<td>Quality by Design</td>
</tr>
<tr>
<td>QbT</td>
<td>Quality by Testing</td>
</tr>
<tr>
<td>R²</td>
<td>Regression coefficient</td>
</tr>
<tr>
<td>RSD</td>
<td>Relative standard deviation</td>
</tr>
<tr>
<td>SPION</td>
<td>Super paramagnetic iron oxide</td>
</tr>
<tr>
<td>TGA</td>
<td>Thermogravimetric analysis or thermal gravimetric analysis</td>
</tr>
<tr>
<td>USP</td>
<td>United State Pharmacopeia</td>
</tr>
<tr>
<td>UV\Vis</td>
<td>Ultraviolet-visible Spectroscopy</td>
</tr>
<tr>
<td>VIP</td>
<td>Variable important plot</td>
</tr>
<tr>
<td>XRD</td>
<td>X-Ray Diffraction</td>
</tr>
</tbody>
</table>